OLX-302

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameOLX-302

Drug Alias NameCell penetrating asymmetric siRNA (OliX Pharmaceuticals)self-delivering RNAi agent for proliferative diabetic retinopathy (OliX Pharmaceuticals)OLX-302

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsDiabetic Retinopathy

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesOlix Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOlix Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsDiabetic Retinopathy

Other Information

ATC CodeN/A